Crystalline forms of a fgfr inhibitor and processes for preparing the same
AssigneeIncyte Corporation
InventorsYongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Claims62
A solid form of Compound 1 having the formula:
- or a salt thereof.
A process for preparing Form I of Compound 1:
- comprising dissolving Compound 1 in a solvent to form a solution;
- and isolating Form I from the solution.
A process for preparing Compound 1:
- or a salt thereof, comprising:
- converting Compound 8:
- to Compound 9:
- converting Compound 9 to Compound 10:
- converting Compound 10 to Compound 11:
- converting Compound 11 to Compound 12 diacetate:
- converting Compound 12 diacetate to Compound 12 hydrochloride:
- converting Compound 12 hydrochloride to Compound 1.
A process for preparing Compound 1:
- or a salt thereof, comprising converting Compound 12 or a salt thereof to Compound 1.
A compound which is selected from:
- or a salt thereof.
A compound which is selected from:
Dependencies are inferred from the claim text.